Quoin Pharmaceuticals (QNRX) announced the FDA has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan Drug Designation by the European Medicines Agency in May 2025. QRX003 lotion is being evaluated in two late-stage whole body pivotal clinical trials for Netherton Syndrome. Enrollment is expected to be completed in first quarter 2026, top-line data is anticipated in the second half of 2026, and NDA submission is planned later in the year.
Shares of Quoin are up 8% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.